RxDoctor Payments Data

Meghan Price

Family · Anderson, INNPI 1225509615

Payments from drug & device makers

$7,102in general payments, 2019–2025

Across 294 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$998
  • Novartis$783
  • Abbott$520
  • Amgen$502
  • Esperion Therapeutics, Inc.$361
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,88297%
  • Education$2203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,102 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan415$452,532
Repatha SureclickEvolocumab260$287,833
JardianceEmpagliflozin237$235,610
FarxigaDapagliflozin Propanediol153$128,047
EliquisApixaban118$118,434
Praluent PenAlirocumab38$31,384
OzempicSemaglutide21$28,980
NexlizetBempedoic Acid/Ezetimibe46$25,364
BrilintaTicagrelor11$12,862
NexletolBempedoic Acid20$10,887
VascepaIcosapent Ethyl23$9,550
Icosapent Ethyl24$6,861
XareltoRivaroxaban12$6,626
Torsemide287$4,416
Metoprolol Succinate244$3,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$783$452,532415 claims
Boehringer IngelheimJardiance$998$235,610237 claims
AstraZenecaFarxiga, Brilinta$1,702$140,909164 claims
PfizerEliquis$108$118,434118 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$361$36,25166 claims
Novo NordiskOzempic$138$28,98021 claims
Johnson & JohnsonXarelto$124$6,62612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Anderson

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →